Overview
Gaucher disease type 2, also called acute neuronopathic Gaucher disease or infantile cerebral Gaucher disease, is a very rare and severe inherited condition. It belongs to a group of diseases called lysosomal storage disorders. In Gaucher disease type 2, the body does not make enough of an enzyme called glucocerebrosidase. This enzyme is responsible for breaking down a fatty substance called glucocerebroside. Without enough of this enzyme, the fatty substance builds up inside cells throughout the body, especially in the brain, liver, spleen, and bone marrow. This buildup causes serious damage to many organs, but the brain damage is the most severe part of this condition. Babies with Gaucher disease type 2 usually appear healthy at birth but begin showing symptoms within the first few months of life. The brain and nervous system are severely affected, leading to problems with movement, swallowing, and breathing. The liver and spleen also become very enlarged. Unlike other types of Gaucher disease, the neurological damage in type 2 progresses very rapidly and cannot be stopped with currently available treatments. There is currently no cure for Gaucher disease type 2. Enzyme replacement therapy, which works well for type 1 Gaucher disease, does not cross into the brain and therefore cannot treat the neurological symptoms. Care is focused on keeping the baby as comfortable as possible and supporting the family. Research into new treatments, including gene therapy and substrate reduction therapy, is ongoing but has not yet produced an effective option for this form of the disease.
Key symptoms:
Enlarged liver and spleen (belly looks swollen or feels hard)Severe brain and nervous system damageMuscle stiffness or spasmsDifficulty swallowingBreathing problemsAbnormal eye movements (eyes move in unusual ways)SeizuresLoss of previously gained developmental skillsFailure to thrive or poor weight gainExtreme muscle weakness or floppinessSkin may appear yellowish (jaundice) in some casesAnemia (low red blood cells, causing paleness and tiredness)
Clinical phenotype terms (33)— hover any for plain English
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Infantile
Begins in infancy, roughly 1 month to 2 years old
FDA & Trial Timeline
9 eventsShenzhen Geno-Immune Medical Institute — PHASE1, PHASE2
Shenzhen Geno-Immune Medical Institute — PHASE1, PHASE2
Prof. Dr. Dirk Reinhardt — PHASE1
EMD Serono Research & Development Institute, Inc. — PHASE1
Margaret Gatti-Mays — PHASE1, PHASE2
UNC Lineberger Comprehensive Cancer Center — EARLY_PHASE1
Shenzhen Geno-Immune Medical Institute — PHASE1, PHASE2
Shenzhen Geno-Immune Medical Institute — PHASE1, PHASE2
Shenzhen Geno-Immune Medical Institute — PHASE1, PHASE2
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Gaucher disease type 2.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Gaucher disease type 2 at this time.
New trials open frequently. Follow this disease to get notified.
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Gaucher disease type 2.
Community
No community posts yet. Be the first to share your experience with Gaucher disease type 2.
Start the conversation →Latest news about Gaucher disease type 2
Disease timeline:
New recruiting trial: Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
A new clinical trial is recruiting patients for Gaucher disease type 2
New recruiting trial: Combination Immunotherapy Targeting Melanoma
A new clinical trial is recruiting patients for Gaucher disease type 2
New recruiting trial: GD2/CD56 Bi-specific CAR-T Cell Therapy
A new clinical trial is recruiting patients for Gaucher disease type 2
New recruiting trial: Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma
A new clinical trial is recruiting patients for Gaucher disease type 2
New recruiting trial: GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
A new clinical trial is recruiting patients for Gaucher disease type 2
New recruiting trial: GD2/PSMA Bi-specific CAR-T Cell Therapy
A new clinical trial is recruiting patients for Gaucher disease type 2
New recruiting trial: Anti-GD2 ADC M3554 in Advanced Solid Tumors
A new clinical trial is recruiting patients for Gaucher disease type 2
New recruiting trial: Study on GD2 Positive Solid Tumors by 4SCAR-GD2
A new clinical trial is recruiting patients for Gaucher disease type 2
New recruiting trial: CAR T Cells to Target GD2 for DMG
A new clinical trial is recruiting patients for Gaucher disease type 2
New recruiting trial: GD2/CD70 Bi-specific CAR-T Cell Therapy
A new clinical trial is recruiting patients for Gaucher disease type 2
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What specific mutations were found in my child's GBA1 gene, and what do they mean for the disease course?,Will enzyme replacement therapy help my child, and what symptoms can it realistically improve?,Are there any clinical trials or experimental treatments available that we should consider?,When should we involve a palliative care team, and what does palliative care look like for this condition?,What signs should prompt us to go to the emergency room immediately?,What support services — such as home nursing, respite care, or counseling — are available to our family?,What are the chances that future children we have could also be affected, and what prenatal testing options exist?
Common questions about Gaucher disease type 2
What is Gaucher disease type 2?
Gaucher disease type 2, also called acute neuronopathic Gaucher disease or infantile cerebral Gaucher disease, is a very rare and severe inherited condition. It belongs to a group of diseases called lysosomal storage disorders. In Gaucher disease type 2, the body does not make enough of an enzyme called glucocerebrosidase. This enzyme is responsible for breaking down a fatty substance called glucocerebroside. Without enough of this enzyme, the fatty substance builds up inside cells throughout the body, especially in the brain, liver, spleen, and bone marrow. This buildup causes serious damage
How is Gaucher disease type 2 inherited?
Gaucher disease type 2 follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Gaucher disease type 2 typically begin?
Typical onset of Gaucher disease type 2 is infantile. Age of onset can vary across affected individuals.
Which specialists treat Gaucher disease type 2?
25 specialists and care centers treating Gaucher disease type 2 are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.